Investing In Health Stocks - How Policy Clarity Is Opening Doors

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Seeking Alpha • Nov 11, 2025

Should You Invest in the VanEck Biotech ETF (BBH)?

The VanEck Biotech ETF (BBH) was launched on December 20, 2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.

Zacks Investment Research • Nov 4, 2025

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.

CNBC Television • Sep 3, 2025

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Seeking Alpha • May 30, 2025

BBH: Fear Of Price Controls Is Not The Problem

The executive order aims to reduce drug prices by allowing direct sales to consumers and cutting out PBMs but faces significant challenges. The main risk for biotech is FDA approval delays due to skepticism from newly appointed officials, impacting funding and development. The VanEck Biotech ETF offers lower risk with established companies, but 23% of AUM in speculative stocks poses a risk.

Seeking Alpha • May 14, 2025

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Seeking Alpha • Feb 25, 2025

VanEck Announces Year-End Distributions for VanEck Equity ETFs

NEW YORK--(BUSINESS WIRE)--VanEck has announced the 2024 annual distributions per share for its VanEck equity exchange-traded funds (ETFs).

Business Wire • Dec 21, 2024

BBH: Buy Rating, As Tech Investors Look Beyond FAANG

Biotechnology sector experiencing exponential growth driven by emerging technologies addressing global challenges. VanEck Biotech ETF tracks top U.S.-listed biotech companies, offers exposure to innovative therapies and technologies. BBH is under-discovered compared to peers, offers potential for trend change in favor of biotech sector.

Seeking Alpha • Jul 23, 2024

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024

I'm on the hunt for ‘Strong Buy' biotech stocks.  According to Finviz.com, there are 680 U.S.-listed biotech stocks.

InvestorPlace • Jun 26, 2024

Biotech ETF (BBH) Hits New 52-Week High

VanEck Biotech ETF BBH is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 21.4% from its 52-week low price of $142.51/share.

Zacks Investment Research • Jun 25, 2024